Skip to contentE
Editas Medicine, Inc.
E
EDITEditas Medicine, Inc. Q1 2024 · 10-Q
Revenue$1.14M$1.14M−88.5% vs Q1 2023 Net Income-$61.95M-$61.95MN/M vs Q1 2023 EPS Diluted-$0.76-$0.76N/M vs Q1 2023 Operating Income-$66,991,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Editas Medicine, Inc. · CIK 1650664 · Engraved from SEC EDGAR
Free Cash Flowderived-$51,743,000N/M Margins · derivedOperating margin-5902.3%−5385.0 pt vs Q1 2023
Net margin-5458.1%−4960.4 pt vs Q1 2023
ended Mar 31, 2024 · filed May 8, 2024 · 38 d after period end